Summary
Based on animal research suggesting that nerve growth factor (NGF) can stimulate central cholinergic neurons, the known losses of cholinergic innervation of the cortices in Alzheimer's disease (AD), and our experience of infusing NGF to support adrenal grafts in parkinsonian patients, we have initiated clinical trials of NGF infusions into the brain of patients with AD. Here we report a follow-up of our first case, a 69-year-old woman, with symptoms of dementia since 8 years. Intraventricular infusion of 6.6 mg NGF during three months resulted in a marked transient increase in uptake and binding of11C-nicotine in frontal and temporal cortex and a persistent increase in cortical blood flow as measured by PET as well as progressive decreases of slow wave EEG activity. After one month of NGF, tests of verbal episodic memory were improved whereas other cognitive tests were not. No adverse effects could be ascribed to the NGF infusion. Taken together, the results of this case study indicate that NGF may counteract cholinergic deficits in AD, and suggest that further clinical trials of NGF infusion in AD are warranted.
Similar content being viewed by others
References
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, third ed (revised). American Psychiatric Association, Washington, DC
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408–417
Buschke H (1973) Selective reminding for analysis of memory and learning. J Verg Learn Verb Behav 12: 543–550
Bäckman L (1986) Adult age differences in cross-modal recoding and mental tempo, and older adults' utilization of compensatory task conditions. Exp Aging Res 12: 135–140
Bäckman L (1991) Recognition memory across the adult life span: the role of prior knowledge. Mem Cogn 19: 63–71
Bäckman L, Josephson S, Herlitz A, Stigsdotter A, Viitanen M (1991) The generalizabiligy of training grains in dementia: effects of an imagery-based mnemonic on face-name retention duration. Psychol Aging 6: 489–492
Chapman CA, Banks BEC, Carstairs JR, Pearce FL, Vernon CA (1979) The preparation of nerve growth factor from the prostate of the guinea-pig and isolation of immunogenically pure material from the mouse submandibular galnd. Fed Eur Biochem Soc Lett 104: 341–344
Ebendal T (1989) NGF in CNS: experimental data and clinical implications. Progr Growth Factor Res 1: 143–159
Ebendal T, Olson L, Seiger Å, Belew M (1984) Nerve growth factors in chick and rat tissues. In: Black I (ed) Cellular and molecular biology of neuronal development. Plenum Press, New York, pp 231–242
Ernfors P, Lindefors N, Chan-Palay V, Persson H (1990) Cholinergic neurons of the nucleus basalis express elevated levels of nerve growth factor receptor mRNA in senile dementia of the Alzheimer type. Dementia 28: 138–145
Fischer W, Wictorin K, Björklund A, Williams LR, Varon S, Gage FH (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65–68
Flynn DD, Mash DC (1986) Characterization of L-3H-nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 47: 1948–1954
Folstein M, Folstein S, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198
Goedert M, Fine A, Dawbarn D, Whilcock CK, Chao MV (1989) Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease. Brain Res Mol Brain Res 5: 1–7
Harbaugh RE (1985) Brain biopsy in Alzheimer's disease: surgical technique and indications. Bull Clin Neurosci 50: 39–43
Harbaugh RE (1986) Intracranial drug administration in Alzheimer's disease. Pyschopharmacol Bull 22: 106–109
Harbaugh RE, Reeder TM, Senter HJ, Knopman DS, Baskin DS, Pirozzolo F, Chang Chui H, Shetter AG, Bakay RA, Leblanc R, Watson RT, DeKosky ST, Schmitt FA, Read SL, Johnston JT (1989) Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. J Neurosurg 71: 481–486
Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6: 2155–2162
Hefti F, Mash DC (1989) Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Aging 10: 75–87
Henriksson BG, Söderström S, Gower, AJ, Ebendal T, Winblad B, Mohammed AK (1991) Hippocampal nerve growth factor levels are related to spatial learning ability in aged rats (in press)
Herscovitch P, Raichle ME, Kilbourn MR, Welch MJ (1987) Positron emission tomographic measurement of cerbral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J Cereb Blood Flow Metab 7: 527–542
Higgins GA, Mufson EJ (1989) NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease. Exp Neurol 106: 222–236
Hill RD, Evankovich KD, Sheikh JI, Yesavage JA (1987) Imagery mnemonic training in a patient with primary degenerative dementia Psychol Aging 2: 204–205
Kaplan DR, Martin-Zanca B, Parada LF (1991) Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF (letter). Nature 350: 158–160
Kausler DH (1982) Experimental psychology and human aging. Wiley, New York
Kerwin J, Morris C, Oakley A, Perry R, Perry E (1991) Distribution of nerve growth factor receptor immunoreactivity in the human hippocampus. Neurosci Lett 121: 178–182
Klein R, Jing SQ, Nanduri V, O'Rourke E, Barbacid M (1991) The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 65: 189–197
Kordower JH, Gash DM, Bothwell M, Hersh L, Mufson EJ (1989) Nerve growth factor receptor and choline acetyltransferase remain colocalized in the nucleus basalis (Ch 4) of Alzheimer patients. Neurobiol Aging 10: 67–74
Levi-Montalcini R (1987) The nerve growth factor: thirty-five years later. EMBO J 6: 1145–1154
Lezak MD (1983) Neuropsychological assessment. Oxford University Press, New York
Långström B, Antoni G, Halldin C, Svärd H, Benson G (1982) The synthesis of some11C-labelled alkaloids Chemica Scripta 20: 46–48
Lärkfors L, Ebendal T (1987) Highly sensitive enzyme immunoassays for β-nerve growth factor. J Immunol Methods 97: 31–47
Lärkfors L, Ebendal T, Whittemore SR, Persson H, Hoffer B, Olson L (1987) Decreased level of nerve growth factor (NGF) and its messenger RNA in the aged rat brain. Mol Brain Res 3: 55–60
Masur DM, Fuld PA, Blau AD, Thal LJ Levin HS, Aronson MK (1989) Distinguishing normal and demented elderly with the selective reminding test. J Clin Exp Neuropsychol 11: 615–630
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA Work Group under the auspices at the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939–944
Mobley WC, Schenker A, Shooter EM (1976) Characterization and isolation of proteolytically modified nerve growth factor. Biochemistry 15: 5543–5552
Nabeshima T, Ogawa S, Ishimaru H, Kameyama T, Fukuta T, Takeuchi R, Hayashi K (1991) Memory impairment and morphological changes in rats induced by active fragment of anti-nerve growth factor-antibody. Biochem Biophys Res Commun 175: 215–219
Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, Andersson Y, Ulin J, Winblad B, Långström B (1990 b) Decreased uptake and binding of11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm [PD-Sect] 2: 215–224
Nordberg A, Hartvig P, Lilja A, Viitanen M, Amberla K, Lundqvist H, Ulin J, Andersson Y, Långström B, Winblad B (1991) Brain nicotinic receptor deficits in Alzheimer patients as studied by positron emisson tomography technique. In: Iqbal K, MacLachan D, Winblad B, Wiesniewski H (ed) Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. John Wiley, New York, pp 517–523
Nordberg A, Winblad B (1986) Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72: 115–119
Nordberg A, Hartvig P, Lundqvist H, Antoni G, Ulin J, Långström B (1989) Uptake and regional distribution of (+)-(R)-and (-)-(S)-N[methyl-11C]-nicotine in the brains of rhesus monkey. An attempt to study nicotinic receptors in vivo. J Neural Transm [PD-Sect] 1: 195–205
Nordberg A, Hartvig P, Lundqvist H, Lilja A, Viitanen M, Amberla K, Ulin J, Winblad B, Långström B (1990 a) Visualization of cholinergic tracers in Alzheimer brains in vivo by positron emission tomography. In: Becker R, Giacobini E (ed) Alzheimer's disease: current research in early diagnosis. Taylor and Francis, New York, pp 329–338
Olson L, Backlund EO, Ebendal T, Freedman R, Hamberger B, Hansson P, Hoffer B, Lindbolm U, Meyersson B, Strömberg I, Sydow O, Seiger Å (1991) Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one-year follow-up of first clinical trial. Arch Neurol 48: 373–381
Palmer MR, Eriksdotter-Nilsson M, Henschen A, Ebendal T, Olson L (1991) Excitatory electrophysiological effects of nerve growth factor on grafted septal neurons (in press)
Perris C, Eisemann M, von Knorring L, Perris H (1984) Presentation of a subscale for the rating of depression and some additional items to the comprehensive psychopathological rating scale. Acta Psychiatr Scand 70: 261–274
Riekkinen P, Buzsaki G, Riekkinen P Jr, Soininen H, Partanen J (1991) The cholinergic system and EEG slow waves. Electroencephalogr Clin Neurophysiol 78: 89–96
Saffran BN, Crutcher KA (1990) NGF-induced remodeling of mature uninjured axon collaterals. Brain Res 525: 11–20
Sharps MJ, Gollin ES (1987) Memoryfor object locations in young and elderly adults. J Geront 42: 336–341
Söderström S, Hallböök CF, Ibáñez CF, Persson H, Ebendal T (1990) Recombinant human β-nerve growth factor (NGF): biological activity and properties in an enzyme immunoassay. J Neurosci Res 27: 665–677
Sutter A, Riopelle RJ, Harris-Warrick RM, Shooter EM (1979) Nerve growth factor receptors. Characterization of two distinct classes of binding sites on chick embryo sensory ganglia cells. J Biol Chem 254: 5972–5982
Thoenen H, Bandtlow C, Heumann R (1987) The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev Physiol Biochem Pharmacol 109: 145–178
Thoenen H, Barde Y-A (1980) Physiology of nerve growth factor. Physiol Rev 60: 1284–1335
Tulving E (1983) Elements of episodic memory. Oxford University Press, New York
Tuszynski MH, UHS, Amaral DC, Gage FH (1990) Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 10: 3604–3614
Ullrich A, Gray A, Berman C, Dull TJ (1983) Human β-nerve growth factor gene sequence highly homologous to that of mouse. Nature 303: 821–825
Wechsler D (1955) Wechsler Adult Intelligence Scale. Manual. Psychological Corp, New York
Whitehouse PJ, Martino A, Antuono P, Lowenstein P, Coyle J, Price D, Kellar K (1986) Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371: 146–151
Whittemore SR, Seiger Å (1987) The expression, localization and functional significance of β-nerve growth factor in the central nervous system. Brain Res Rev 12: 439–464
Will B, Hefti F (1985) Behavioural and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions. Behav Brain Res 17: 17–24
Williams LR, Varon S, Peterson GM, Wictorin K, Björklund A, Gage FH (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci U.S.A. 33: 9231–9235
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olson, L., Nordberg, A., von Holst, H. et al. Nerve growth factor affects11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (Case Report). J Neural Transm Gen Sect 4, 79–95 (1992). https://doi.org/10.1007/BF02257624
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02257624